All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

(+/-)-BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3 beta Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F21%3A10428687" target="_blank" >RIV/00179906:_____/21:10428687 - isvavai.cz</a>

  • Alternative codes found

    RIV/62690094:18470/21:50018074 RIV/60162694:G44__/21:00556982

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=yxs8WYdo6Y" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=yxs8WYdo6Y</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1021/acschemneuro.0c00803" target="_blank" >10.1021/acschemneuro.0c00803</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    (+/-)-BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3 beta Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease

  • Original language description

    Multitarget-directed ligands (MTDLs) are considered a promising therapeutic strategy to address the multifactorial nature of Alzheimer&apos;s disease (AD). Novel MTDLs have been designed as inhibitors of human acetylcholinesterases/ butyrylcholinesterases, monoamine oxidase A/B, and glycogen synthase kinase 3 beta and as calcium channel antagonists via the Biginelli multicomponent reaction. Among these MTDLs, (+/-)-BIGI-3h was identified as a promising new hit compound showing in vitro balanced activities toward the aforementioned recognized AD targets. Additional in vitro studies demonstrated antioxidant effects and brain penetration, along with the ability to inhibit the aggregation of both t protein and beta-amyloid peptide. The in vivo studies have shown that (+/-)-BIGI-3h (10 mg/kg intraperitoneally) significantly reduces scopolamine-induced cognitive deficits.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30104 - Pharmacology and pharmacy

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2021

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    ACS Chemical Neuroscience

  • ISSN

    1948-7193

  • e-ISSN

  • Volume of the periodical

    12

  • Issue of the periodical within the volume

    8

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    15

  • Pages from-to

    1328-1342

  • UT code for WoS article

    000643598600005

  • EID of the result in the Scopus database

    2-s2.0-85104920488